BibTex RIS Cite

Nadir Hastalıklar ve Avrupa Birliği Sağlık Politikasında Derinleşme: Avrupa Referans Ağları

Year 2018, Volume: 3 Issue: 58, 1287 - 1306, 01.01.2018

Abstract

Avrupa Birliği AB entegrasyonu derinleştikçe, AB münhasıran yetkili olmadığı alanlarda da gerektiğinde geniş inisiyatif kullanmaktadır. Sağlık da AB’nin münhasıran yetkili olmadığı alanlardan birisi olmakla birlikte, AB’nin sağlıkla giderek daha çok ilgilendiğini ve özellikle yaşlanan AB nüfusu ve sınır ötesi sağlık bakımı konusunda birçok politika geliştirildiğini görmekteyiz. Nadir hastalıklar da, bütün Avrupa’da çok geniş bir nüfusu etkileyen ve ülkelerin tek başlarına mücadele etmelerinin zor olduğu sağlık sorunlarından birisidir. Son yıllarda nadir hastalıklardaki çağdaş yönetim şeklinin merkezi bir yaklaşım olduğunun kabul edilmesi üzerine AB, buna yönelik olarak hem ülkeleri tek tek güçlendirecek hem de onları bir çatı altında toplayarak bilgi ve deneyim birikimi sağlayacak bir politika geliştirmiştir. AB bu politika bağlamında Avrupa Referans Ağları’nı kurarak nadir hatalıklar alanında yeni bir aşamaya gelmiştir. Kurulma süreci incelendiğinde Avrupa Referans Ağlarının AB sağlık politikasındaki derinleşmenin tipik bir örneği olduğu görülmektedir

References

  • Ayme S, Kole A, Rodwell C. (2011) RDTF Report on Patient registries the field of rare diseases: Overview of the issues surrounding the establishment, governance http://www.eucerd.eu/EUCERD/upload/file/RDTFReportRegistriesJuly2 011.pdf (erişim 10.07.2017) of academic registries,
  • Ayme S, Rodwell C. (2015) Rare disease policies to improve care for patients in Europe Charlotte. Biochimica et Biophysica Acta 1852: 2329–2335
  • Butcher J (2007) Cooperation is key, say neuromuscular-disease researchers. Lancet Neurol 6: 298–99.
  • EU Health programme, (2011). Reaching out to rare disease patients across Europe http://ec.europa.eu/health/rare_diseases/docs/rd_booklet_2011_en.pdf. (erişim 10.07.2017)
  • Franco P. (2013) Orphan drugs: the regulatory environment. Drug Discov Today 18 (3-4):163-172.
  • Orphanet Report Series (2016) Rare Disease Registries in Europe. http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf (erişim 10.07.2017)
  • Richesson R and Vehik K. (2010) Patient registries: Utility, validity and inference. Adv Exp Med Biol. 686: 87-104
  • Rubinstein YA, Groft SC, Bartek R, et al. (2010) Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemporary Clinical Trials 31: 394–404.
  • Schieppati A, Henter J-I, Daina E, Aperia A (2008) Why rare diseases are an important medical and social issue. Lancet 371: 2039–41.
  • Taruscio S, Gainotti E, Mollo L, et al. (2013) The Current Situation and Needs of Rare Disease Registries in Europe. Public Health Genomics 16:288–298
  • WHO Report (2013) Background Paper 6.19 Rare Diseases, Update on 2004 Background Paper Written by S. van Weely, Ph.D. and Prof. H.G.M. Leufkens. By R. de Vrueh, Ph.D., E.R.F.Baekelandt, and J.M.H. de Haan. http://www.who.int/medicines/areas/priority_medicines/BP6_19Rare.pdf (erişim 10.07.2017)

Rare Diseases and deepening in the European Union’s health policy: European Reference Networks

Year 2018, Volume: 3 Issue: 58, 1287 - 1306, 01.01.2018

Abstract

As the European Union’s EU integration deepens, when needed the EU takes the initiative widely in areas that it has no exclusive competence. Although the health is not an area that the EU has an exclusive competence, we see that the EU is getting interested in healt by the time and devolops many policies particularly in the aging European population and crossborder healthcare. Rare diseases are one of the health problems that affects a large population all over Europe and it’s difficult for countries to fight alone. In the recent years, as it is accepted that current managment method in the the rare diseases is a central approach, the EU has devoloped a policy that both strenghtens the countries one by one and gather them under the same roof to provide an accumulation of knowledge and experience. In this context of policy, the EU has come to a new stage in the area of rare diseases by establishing the European Reference Networks. When the establishment process is examined, it appears that the European Reference Networks is a typical example of the deepening of the EU’s health policy.

References

  • Ayme S, Kole A, Rodwell C. (2011) RDTF Report on Patient registries the field of rare diseases: Overview of the issues surrounding the establishment, governance http://www.eucerd.eu/EUCERD/upload/file/RDTFReportRegistriesJuly2 011.pdf (erişim 10.07.2017) of academic registries,
  • Ayme S, Rodwell C. (2015) Rare disease policies to improve care for patients in Europe Charlotte. Biochimica et Biophysica Acta 1852: 2329–2335
  • Butcher J (2007) Cooperation is key, say neuromuscular-disease researchers. Lancet Neurol 6: 298–99.
  • EU Health programme, (2011). Reaching out to rare disease patients across Europe http://ec.europa.eu/health/rare_diseases/docs/rd_booklet_2011_en.pdf. (erişim 10.07.2017)
  • Franco P. (2013) Orphan drugs: the regulatory environment. Drug Discov Today 18 (3-4):163-172.
  • Orphanet Report Series (2016) Rare Disease Registries in Europe. http://www.orpha.net/orphacom/cahiers/docs/GB/Registries.pdf (erişim 10.07.2017)
  • Richesson R and Vehik K. (2010) Patient registries: Utility, validity and inference. Adv Exp Med Biol. 686: 87-104
  • Rubinstein YA, Groft SC, Bartek R, et al. (2010) Creating a global rare disease patient registry linked to a rare diseases biorepository database: Rare Disease-HUB (RD-HUB). Contemporary Clinical Trials 31: 394–404.
  • Schieppati A, Henter J-I, Daina E, Aperia A (2008) Why rare diseases are an important medical and social issue. Lancet 371: 2039–41.
  • Taruscio S, Gainotti E, Mollo L, et al. (2013) The Current Situation and Needs of Rare Disease Registries in Europe. Public Health Genomics 16:288–298
  • WHO Report (2013) Background Paper 6.19 Rare Diseases, Update on 2004 Background Paper Written by S. van Weely, Ph.D. and Prof. H.G.M. Leufkens. By R. de Vrueh, Ph.D., E.R.F.Baekelandt, and J.M.H. de Haan. http://www.who.int/medicines/areas/priority_medicines/BP6_19Rare.pdf (erişim 10.07.2017)
There are 11 citations in total.

Details

Primary Language Turkish
Journal Section Research Article
Authors

İbrahim Gülhan This is me

Publication Date January 1, 2018
Published in Issue Year 2018 Volume: 3 Issue: 58

Cite

APA Gülhan, İ. (2018). Nadir Hastalıklar ve Avrupa Birliği Sağlık Politikasında Derinleşme: Avrupa Referans Ağları. Çalışma Ve Toplum, 3(58), 1287-1306.

muratozverister@gmail.com
dergicalismavetoplum@gmail.com
www.calismatoplum.org